Molin K, Rieger A
Acta Chir Scand. 1979;145(3):177-83.
A prospective randomized study on the effects of Enterobiotic (oxytetracycline + neomycin) given per os to patients operated upon electively and curatively for carcinoma coli and recti is presented. 75 patients were treated and 66 were controls. A highly significant reduction of peroperative total and Gram-negative bacterial growth from the bowel was registered and a probably significant reduction of anaerobic bacterial growth. In the whole material a highly significant lower incidence of wound sepsis and intra-abdominal infectious complications occurred in the treated group, compared with the control group. This applies also to the resection material, while the difference is of probable significance in the excision group. 13 of 66 patients died, 8 of septic complications, all in the non-treated group. There was no mortality in the pretreated group. The difference between the noninfected and the infected patient groups was significant as regards the preoperative intraluminal total growth of bacteria and the growth of Gram-negative bacteria. The subsequent non-infected patients show a significantly increased number of cultures not showing any growth of bacteria. No negative side effects of Enterobiotic therapy were noted.
本文介绍了一项前瞻性随机研究，该研究针对因结肠癌和直肠癌接受择期根治性手术的患者口服肠生素（土霉素+新霉素）的效果。共治疗75例患者，66例为对照组。结果显示，术中肠道内总的细菌生长以及革兰氏阴性菌生长显著减少，厌氧菌生长可能也有显著减少。在整个样本中，与对照组相比，治疗组伤口感染和腹腔内感染并发症的发生率显著降低。这一情况在切除样本中同样如此，而在切除组中差异可能具有显著性。66例患者中有13例死亡，8例死于感染性并发症，均在未治疗组。预处理组无死亡病例。在术前管腔内细菌总生长以及革兰氏阴性菌生长方面，未感染患者组和感染患者组之间的差异具有显著性。随后未感染的患者中，培养未显示任何细菌生长的数量显著增加。未观察到肠生素治疗的负面副作用。
